Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05863351 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion moved earlier from Dec 1, 2030 to Aug 31, 2027 Show 6 more changesShow less
    • Start date: Sep 7, 2023 to Dec 27, 2023
    • Study completion moved earlier from Aug 1, 2037 to Aug 31, 2028
    • Eligibility criteria expanded, about 41 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description revised
    • Site details revised at 10 of 108 sites
  2. 5 versions Re-verified since Feb 27, 2026, no change to tracked fieldsv14-v18
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 108 of 108 sites
    v13
  4. 5 versions Re-verified since Aug 15, 2025, no change to tracked fieldsv8-v12
  5. Study sites: 103 to 108v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 98 to 103v6
  2. Study sites: 89 to 98v5
  3. Re-verified, no change to tracked fieldsv4
  4. Study sites: 10 to 89v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 10
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in the body (metastatic). Study doctors want to find out if this approach is better or worse than the usual approach for metastatic kidney cancer. The usual approach is defined as the care most people get for metastatic kidney cancer which includes systemic therapy such as immunotherapy (given through the veins) and/or small molecular inhibitor (tablets taken by mouth). Radiotherapy uses high energy x-rays to kill cancer cells and shrink tumors. SAbR uses special equipment to position a patient and deliver radiation to tumors with high precision. Giving SAbR prior to systemic therapy may kill more tumor cells than the usual approach, which is systemic therapy alone.
Trial Details
NCT Number NCT05863351
Lead Sponsor ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Related terms Carcinoma, Renal Cell
Enrollment 472 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov